The following video is part of our "Motley Fool Conversations" series, in which, Andrew Tonner, technology editor and analyst, and David Williamson, health-care editor and analyst, discuss topics across the investing world.

In today's edition, they discuss Cell Therapeutics, which has had a roller coaster of a week. After receiving word that its lead drug candidate, pixantrone, had been accepted for FDA review, shares gained 24%. Unfortunately for investors, the company used the higher share price to announce an equity offering worth $20 million, sending shares plummeting back down. Our Motley Fool analysts discuss the news and examine what approval of pixantrone could mean for investors.

Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that's revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.